Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events

[1] Lennernäs H(1997)Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors Clin-Pharmacokinet 32 403-425

[2] Fager G(2016)Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate Lyase Curr Atheroscler Rep 18 61-1822

[3] Bilen O(2017)Focused update of the 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways J Am Coll Cardiol 70 1785-6

[4] Ballantyne CM(2008)Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia J Cardiol 52 1-167

[5] Lloyd-Jones DM(2016)PCSK9 inhibitors—mechanisms of action Aust Prescr 39 164-1272

[6] Morris PB(2006)Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 1264-153

[7] Ballantyne CM(2007)Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus Drugs 67 121-1000

[8] Miura S(2008)Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing Vasc Health Risk Manag 4 991-1574

[9] Saku K(2010)Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 1563-1005

[10] Page MM(2003)Niacin for dyslipidemia: considerations in product selection Am J Health Syst Pharm 60 995-2267

[1] Lennernäs H(1997)Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors Clin-Pharmacokinet 32 403-425

[2] Fager G(2016)Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate Lyase Curr Atheroscler Rep 18 61-1822

[3] Bilen O(2017)Focused update of the 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways J Am Coll Cardiol 70 1785-6

[4] Ballantyne CM(2008)Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia J Cardiol 52 1-167

[5] Lloyd-Jones DM(2016)PCSK9 inhibitors—mechanisms of action Aust Prescr 39 164-1272

[6] Morris PB(2006)Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 1264-153

[7] Ballantyne CM(2007)Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus Drugs 67 121-1000

[8] Miura S(2008)Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing Vasc Health Risk Manag 4 991-1574

[9] Saku K(2010)Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 1563-1005

[10] Page MM(2003)Niacin for dyslipidemia: considerations in product selection Am J Health Syst Pharm 60 995-2267